Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in immunostimulatory CpG oligonucleotides.

Simon Rothenfusser1, Evelyn Tuma, Moritz Wagner

  • 1Department of Internal Medicine, Division of Clinical Pharmacology, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany.

Current Opinion in Molecular Therapeutics
|May 30, 2003
PubMed
Summary

Synthetic CpG oligonucleotides (CpG ODNs) are potent immune stimulants and vaccine adjuvants. Research reveals distinct CpG DNA effects in mice and humans, highlighting plasmacytoid dendritic cells and B-cells as key responders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 disrupted patterns of cause-specific mortality in Switzerland.

International journal of public health·2026
Same author

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same author

Dose Recommendations for Drugs in Patients With Liver Cirrhosis (The ALIVe Study): Protocol for a Multiphase Validation and Consensus Study.

JMIR research protocols·2026
Same author

5'-Triphosphate guanosine RNAs recruit GTP-binding proteins to suppress RIG-I/IFN type I signaling.

Molecular cell·2026
Same author

Assessment of Swelling, Function, and Pain Following the Tourniquet Use in Total Knee Arthroplasty.

The journal of knee surgery·2026
Same author

RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells.

International journal of molecular sciences·2026

Area of Science:

  • Immunology
  • Molecular Biology
  • Vaccinology

Background:

  • The vertebrate immune system detects microbial CpG DNA via Toll-like receptor-9 (TLR9).
  • Synthetic CpG oligonucleotides (CpG ODNs) are recognized as powerful immunomodulatory agents and vaccine adjuvants.
  • Recent research highlights significant differences in CpG DNA immunological effects between mouse and human systems.

Purpose of the Study:

  • To elucidate the distinct immunological roles of CpG DNA in vertebrate systems.
  • To identify key immune cell subsets involved in CpG DNA recognition and response.
  • To explore the potential of novel CpG ODNs as therapeutic agents.

Main Methods:

  • Investigated the immune response to CpG DNA in mouse and human models.
  • Identified and characterized CpG-sensitive immune cell populations, specifically plasmacytoid dendritic cells (PDCs) and B-cells.

Related Experiment Videos

  • Developed and tested novel CpG ODNs with tailored functional activities.

    • Main Results:

    • Plasmacytoid dendritic cells (PDCs) are pivotal in mediating CpG-induced immune responses in humans.
    • B-cells, alongside PDCs, are the primary CpG-sensitive immune cells in humans expressing Toll-like receptor-9 (TLR9).
    • Novel CpG ODNs exhibiting distinct functional activities were identified based on insights from these key cell types.

    Conclusions:

    • Understanding the distinct roles of PDCs and B-cells in CpG DNA recognition is crucial for therapeutic development.
    • CpG ODNs represent a promising class of molecular therapeutics, particularly as vaccine adjuvants.
    • Further research and clinical development are warranted for CpG ODN-based therapies.